DOCSLIB.ORG

Comprehensive List of Cross-Reactive and Non Cross-Reactive Compounds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Comprehensive List of Cross-Reactive and Non Cross-Reactive Compounds Rev.A 10-8-2002 TOX Specificity-Chemical Name Biosite Inc. Page 1 Highest Conc. Tested Conc. Giving Positive TRADE NAME CHEMICAL NAME DRUG CLASS (ng/ml) (ng/ml) Sectral Acebutolol Antihypertensive 100,000 Ethanal Acetaldehyde Solvent 10,000,000 Tylenol/Paracetamol/APAP Acetaminophen Analgesic 1,000,000 Acetanilide Acetanilide Analgesic 100,000 Diamox Acetazolamide Diuretic 100,000 Dymelor Acetohexamide Antidiabetic 1,000,000 Acetone Acetone Solvent 10,000,000 Notensil Acetopromazine Tranquilizer 100,000 Mucomyst Acetyl-l-cysteine, N- Mucolytic 100,000 LAAM Acetylmethadol, l-a- Narcotic analgesic 100,000 Aspirin Acetylsalicylic acid Analgesic 1,000,000 Aspirin metabolite Acetylsalicylic acid metab.(Salicylic acid) Aspirin metabolite 1,000,000 Aspirin metabolite Acetylsalicylic acid metab.(Salicyluric acid) Aspirin metabolite 100,000 Acyclovir Acyloguanosine Antiviral 100,000 Dowacide Q Adamantane, (1-(3-Chloroallyl)-3,5,7-triaza-1-azonia)- Antibacterial 100,000 Gumbaral Adenosylmethionine, S- Anti-inflammatory 100,000 Deracyn Adinazolam Benzodiazepine 100,000 BZO 1,000 Deracyn metabolite Adinazolam, Desmethyl Benzodiazepine metabolite 100,000 BZO 250 HSA Albumin, Human Protein 5,000,000 Proventil/Ventolin Albuterol Bronchodilator 200,000 Octalene Aldrin Insecticide 100,000 Fosamax Alendronate Bone reabsorption inhibitor 200,000 Diadol Allobarbital Barbiturate 100,000 BAR 150 Zyloprim Allopurinol Antiurolithic 100,000 Nisentil Alphaprodine Narcotic analgesic 100,000 Xanax Alprazolam Benzodiazepine 100,000 BZO 100 Xanax metabolite Alprazolam, 4-Hydroxy- Benzodiazepine metabolite 100,000 BZO 250 Xanax metabolite Alprazolam-glucuronide, a-Hydroxy Benzodiazepine metabolite 5,000 BZO 150 Xanax metabolite Alprazolam, a-Hydroxy- Benzodiazepine metabolite 100,000 BZO 50 Regletin Alprenolol Antiarrhythmic 200,000 Symmetrel Amantadine Antiviral 100,000 Cylocort Amcinonide Glucocorticoid 100,000 Amikin Amikacin Antibacterial 100,000 Midamor Amiloride Diuretic 100,000 Survector Amineptine CNS Stimulant 100,000 Sources: 1. Merck Index 2.Disposition of Toxic Drugs Chemicals in Man 3. Physicians Desk Reference 2000 Rev.A 10-8-2002 TOX Specificity-Chemical Name Biosite Inc. Page 2 Highest Conc. Tested Conc. Giving Positive TRADE NAME CHEMICAL NAME DRUG CLASS (ng/ml) (ng/ml) Cytradren Aminoglutethimide Anticonvulsant 100,000 Heptin Aminoheptane, 2- Adrenergic 100,000 Ampyrone Aminopyrine, l- Antipyretic 100,000 Menocil Aminorex Anorexic 100,000 Menocil metabolite (Euphoria) Aminorex metab.(Methylaminorex, 4-) Anorexic metabolite 100,000 Cordarone Amiodarone Antiarrhythmic 100,000 Solian Amisulpiride Antipsychotic 1,000,000 Elavil Amitriptyline Tricyclic antidepressant 100,000 TCA 750 also metabolizes to Nortriptyline Elavil metabolite Amitriptyline metabolite(d,l-E-10-Hydroxy-Amitriptyline) Amitriptyline metabolite 100,000 TCA 250 Samiac Ammonium chloride Expectorant 200,000 Amytal Amobarbital Barbiturate 100,000 BAR 100 Ascendin Amoxapine Antidepressant 100,000 Amoxil Amoxicillin Antibacterial 100,000 Amphetamine analog Amphetamine analog(Ethylamphetamine, N-) Amphetamine analog 100,000 MeAMP 12,500 Paredrine Amphetamine analog(Hydroxyamphetamine, p-) Amphetamine analog 200,000 AMP 20,000 Adderall metabolite Amphetamine metab.(Hippuric acid) Amphetamine metabolite 100,000 Adderall metabolite Amphetamine metab.(Hydroxynorephedrine, p-) Amphetamine metabolite 100,000 Adderall/Dexedrine/Benzadrine Amphetamine, d- Amphetamine 100,000 AMP 1,000 Cydril Amphetamine, l- Amphetamine 100,000 AMP 63,500 Ambisone Amphotericin Antifungal 100,000 Ampicin Ampicillin Antibacterial 100,000 Laetrile Amygdalin Antineoplastic 1,000,000 Kyanol Aniline Dye 200,000 Analgesine Antipyrine Analgesic 1,000,000 Apocodeine Apocodeine Emetic 100,000 Euporphin Apomorphine Emetic 100,000 Alurate Aprobarbital Barbiturate 100,000 BAR 200 Vitamin C Ascorbic acid Vitamin 1,500,000 Nutrasweet Aspartame Sweetener 100,000 Histazol Astemizole Antihistamine 100,000 THC 20,000 Tenormin Atenolol Antihypertensive 100,000 Donnatal Atropine Anticholinergic 100,000 Donnatal metabolite Atropine metab.(Tropic acid) Atropine metabolite 100,000 Donnatal metabolite Atropine metab.(Tropine) Atropine metabolite 2,000,000 OPI 2,000,000 Sources: 1. Merck Index 2.Disposition of Toxic Drugs Chemicals in Man 3. Physicians Desk Reference 2000 Rev.A 10-8-2002 TOX Specificity-Chemical Name Biosite Inc. Page 3 Highest Conc. Tested Conc. Giving Positive TRADE NAME CHEMICAL NAME DRUG CLASS (ng/ml) (ng/ml) Lipitor Atorvastatin Antihyperlipidemic 100,000 Rynatan/Trinalin Azatadine Antihistaminic 100,000 Imuran Azathioprine Antirheumatic 100,000 Baclon Baclofen Muscle relaxant 10,000 Barbitone Barbital Barbiturate 100,000 BAR 150 Malonylurea Barbituric acid Manuf. plastics 100,000 BDB BDB(d,l-1-(3,4-Methylenedioxyphenyl)-2-Butanamine) MBDB metabolite 100,000 AMP 2,500 Vanceril Beclomethasone Antiasthmatic 1,000,000 Mikedimide Bemegride Analeptic 100,000 Cedad Benactyzine Antidepressant 100,000 Corzide Bendroflumethiazide Diuretic 100,000 Benzidine Benzidine Dye 100,000 Americaine Benzocaine Anesthetic 100,000 Urised Benzoic acid Antifungal 100,000 Tessalon Benzonatate Antitussive 1,000,000 Didrex Benzphetamine Anorexic 100,000 also metabolizes to Amphetamine & Methamphetamine Proaqua Benzthiazide Diuretic 100,000 Cogentin Benztropine mesylate Anticholinergic 100,000 Phenylmethanol Benzyl alcohol Antimicrobial 1,000.00 Bepadin/Vascor Bepridil Antianginal 100,000 Berberine Berberine Antibacterial 100,000 Celestone Betamethasone Glucocorticoid 100,000 Urecholine Bethanechol Cholinergic 100,000 Bilirubin Bilirubin Bile pigment 2,500 Akineton Biperiden Anticholinergic 100,000 Dulcolax Bisacodyl Cathartic 100,000 Durazanil Bromazepam Benzodiazepine 100,000 BZO 750 Durazanil metabolite Bromazepam,Hydroxylated cleavage product Benzodiazepine metabolite 100,000 BZO 50,000 Somnurol Bromisovalum Sedative 5,000,000 Parlodel Bromoergocryptine, 2-a- Antiparkinsonian 100,000 Dimetane Brompheniramine Antihistaminic 100,000 Mappine Bufotenine Hallucinogen 100,000 Bumex Bumetanide Diuretic 100,000 Marcaine/Sensorcaine Bupivacaine Anesthetic 1,000,000 Sources: 1. Merck Index 2.Disposition of Toxic Drugs Chemicals in Man 3. Physicians Desk Reference 2000 Rev.A 10-8-2002 TOX Specificity-Chemical Name Biosite Inc. Page 4 Highest Conc. Tested Conc. Giving Positive TRADE NAME CHEMICAL NAME DRUG CLASS (ng/ml) (ng/ml) Buprenex Buprenorphine Narcotic analgesic 1,000,000 Wellbutrin/Zyban Bupropion Antidepressant 1,000,000 Wellbutrin/Zyban metabolite Bupropion metabolite Antidepressant 100,000 BuSpar Buspirone Anxiolytic 1,000,000 Butisol Butabarbital Barbiturate 100,000 BAR 200 Butelline Butacaine Anesthetic 100,000 Fiorinal/Phrenilin Butalbital Barbiturate 100,000 BAR 150 Soneryl Butethal Barbiturate 100,000 BAR 50 Stadol Butorphanol Narcotic analgesic 100,000 Butanal Butyraldehyde Solvent 100,000 Caffeine Caffeine Stimulant 2,000,000 Caffeine metabolite Caffeine metab.(Dimethyluric acid, 1,7-) Caffeine metabolite 100,000 Caffeine metabolite Caffeine metab.(Dimethyluric acid, 1,9-) Caffeine metabolite 100,000 Caffeine metabolite Caffeine metab.(Dimethyluric acid, 3,7-) Caffeine metabolite 100,000 Caffeine metabolite Caffeine metab.(Dimethyluric acid, 3,9-) Caffeine metabolite 100,000 Caffeine metabolite Caffeine metab.(Dimethyluric acid, 7,9-) Caffeine metabolite 100,000 Caffeine metabolite Caffeine metab.(Paraxanthine) Caffeine metabolite 100,000 Camphor Camphor Topical Antiseptic 100,000 Phanurane Canrenoic acid Diuretic 100,000 Zostrix Capsaicin Topical analgesic 100,000 Capoten Captopril Antihypertensive 100,000 Carcholin Carbachol Cholinergic 100,000 Tegretol Carbamazepine Anticonvulsant 100,000 THC 10,000 Tegretol metabolite Carbamazepine metab.(Iminostilbene) Carbamazepine metabolite 100,000 Tegretol metabolite Carbamazepine, 10,11-Dihydroxy- Carbamazepine metabolite 100,000 THC 60,000 Tegretol metabolite Carbamazepine-10,11-epoxide Carbamazepine metabolite 100,000 Mycholine Carbamyl-ß-methylcholine chloride Cholinergic 200,000 Carbylderm Carbaryl Pediculocide 100,000 Sinemet Carbidopa Antiparkinsonian 1,000,000 Paraplatin Carboplatin Antineoplastic 100,000 Carbital Carbromal Sedative 5,000,000 Soma Carisoprodol Muscle relaxant 100,000 also metabolizes to Meprobamate Khat/Qat (Catha edulis ) Cathinone Stimulant 100,000 Ceclor Cefaclor Antibacterial 100,000 Sources: 1. Merck Index 2.Disposition of Toxic Drugs Chemicals in Man 3. Physicians Desk Reference 2000 Rev.A 10-8-2002 TOX Specificity-Chemical Name Biosite Inc. Page 5 Highest Conc. Tested Conc. Giving Positive TRADE NAME CHEMICAL NAME DRUG CLASS (ng/ml) (ng/ml) Duricef Cefadroxil Antibacterial 100,000 Claforan Cefotaxime Antibacterial 100,000 Mefoxin Cefoxitin Antibacterial 100,000 Rocefin Ceftriaxone Antibacterial 100,000 Ceftin Cefuroxime Antibacterial 100,000 Celebrex Celecoxib Anti-imflammatory 200,000 Keflex Cephalexin Antibacterial 100,000 Ceporan Cephaloridine Antibacterial 100,000 Cesporan Cephradine Antibacterial 200,000 Baycol Cerivastatin Antihyperlipidemic 10,000 Somnos Chloral hydrate Hypnotic 100,000 Somnos metabolite Chloral hydrate metab.(Trichloroethanol) Chloral hydrate metabolite 100,000 Dorcalm Chloralose, a- Sedative 100,000 Chloromycetin Chloramphenicol Antibacterial 100,000 Trihistan Chlorcyclizine Antihistamine 100,000 Kepone Chlordecon Insecticide 100,000 Librium Chlordiazepoxide Benzodiazepine 100,000 BZO 13,000 also metabolizes to Demoxepam & Oxazepam glucuronide Librium
Recommended publications
  • (125I)Iodoazidococaine, a Photoaffinity Label for the Haloperidol-Sensitive Sigma Receptor (Cocaine/[3H]Cocaine Binding/Cocaine-Binding Protein) JOHN R

    (125I)Iodoazidococaine, a Photoaffinity Label for the Haloperidol-Sensitive Sigma Receptor (Cocaine/[3H]Cocaine Binding/Cocaine-Binding Protein) JOHN R

    Proc. Natl. Acad. Sci. USA Vol. 89, pp. 1393-1397, February 1992 Biochemistry (125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor (cocaine/[3H]cocaine binding/cocaine-binding protein) JOHN R. KAHOUN AND ARNOLD E. RuOHO* Department of Pharmacology, University of Wisconsin Medical School, Madison, WI 53706 Communicated by James A. Miller, October 8, 1991 (received for review July 10, 1991) ABSTRACT A carrier-free radioiodinated cocaine photo- cifically block the photolabeling ofthe DA transporter, it was affinity label, (-)-3-('25I)iodo-4-azidococaine [('25I)IACoc], not established whether cocaine bound directly to this protein has been synthesized and used as a probe for cocaine-binding or to an associated protein. Recently, the human NE trans- proteins. Photoaffinity labeling with 0.5 nM ('25I)IACoc re- porter has been expression-cloned as cDNA and overex- sulted in selective derivatization of a 26-kDa polypeptide with pressed in HeLa cells (13). The ability of cocaine to block the pharmacology of a sigma receptor in membranes derived [3H]NE uptake into these HeLa cells provides good evidence from whole rat brain, rat liver, and human placenta. Covalent that cocaine binds directly with this transporter. labeling of the 26-kDa polypeptide was inhibited by 1 FM Although cocaine has been shown to block the binding of haloperidol, di(2-tolyl)guanidine (DTG), 3-(3-hydroxyphenyl)- sigma ligands to rat and guinea pig brain membranes with N-(1-propyl)piperidine (3-PPP), dextromethorphan, and car- relatively low affinity, the nature and physiological impor- betapentane. Stereoselective protection of (125I)IACoc photo- tance of this interaction is not known.
  • Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • PROZAC Product Monograph Page 1 of 49 Table of Contents

    PROZAC Product Monograph Page 1 of 49 Table of Contents

    PRODUCT MONOGRAPH PrPROZAC® fluoxetine hydrochloride 10 mg and 20 mg Capsules Antidepressant / Antiobsessional / Antibulimic © Eli Lilly Canada Inc. Date of Revision: January, 25 Exchange Tower 2021 130 King Street West, Suite 900 PO Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Submission Control No: 192639 PROZAC Product Monograph Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS .....................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................5 ADVERSE REACTIONS ...................................................................................................13 DRUG INTERACTIONS....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................27 OVERDOSAGE..................................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY ...............................................................30 STORAGE AND STABILITY............................................................................................32
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry

    Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry

    molecules Article Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry Dasom Shin, Hui-Seung Kang *, Hyungsoo Kim and Guiim Moon New Hazardous Substances Division, Department of Food Safety Evaluation, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Cheongju 28159, Korea; [email protected] (D.S.); [email protected] (H.K.); [email protected] (G.M.) * Correspondence: [email protected] Received: 11 August 2020; Accepted: 17 September 2020; Published: 24 September 2020 Abstract: In this work, liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed and validated for screening and confirmation of 64 illicit compounds in dietary supplements. The target compounds were illegally used pharmaceutical drugs, prohibited compounds, and not authorized ingredients for different therapeutics (sexual enhancement, weight loss, muscular strengthening, and relaxing products). The validation procedure was performed to evaluate selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision according to the Association of Official Analytical Chemists guidelines. The linearity was >0.98 in the range of 1 1 0.5–200 µg L− . The LOQs were in the range 1–10 µg kg− for all target compounds. The accuracy (expressed as recovery) was 78.5–114%. The precision (expressed as the relative standard deviation) was below 9.15%. The developed method was applied for the determination of illicit compounds in dietary supplements collected from websites. As a result, the total detection rate was 13.5% (27 samples detected in 200 samples). The concentrations of detected samples ranged from 0.51 1 to 226 mg g− .
  • Réglementation De La Pharmacie

    Réglementation De La Pharmacie

    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
  • LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22

    LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22

    TIP 22: LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22 A43664 Ira J. Marion, M.A. Consensus Panel Chair U.S. Department of Health and Human Services Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment Rockwall II, 5600 Fishers Lane Rockville, MD 20857 DHHS Publication No. (SMA) 95-3052 Printed 1995. Disclaimer This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. All material appearing in this volume except quoted passages from copyrighted sources is in the public domain and may be reproduced or copied without permission from the Center for Substance Abuse Treatment (CSAT) or the authors. Citation of the source is appreciated. This publication was written under contract number ADM 270-91-0007 from the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration (SAMHSA). Sandra Clunies, M.S., served as the CSAT Government project officer. Robert A. Lubran, M.S., M.P.A., was the Government content advisor. Carolyn Davis, Constance Gartner, Linda Harteker, Lise Markl, Barbara Shapiro, and Deborah Shuman served as writers. The opinions expressed herein are the views of the consensus panel members and do not reflect the official position of CSAT or any other part of the U. S. Department of Health and Human Services (DHHS). No official support or endorsement of CSAT or DHHS for these opinions or for particular instruments or software that may be described in this document is intended or should be inferred. The guidelines proffered in this document should not be considered as substitutes for individualized patient care and treatment decisions.
  • A Systematic Review of Combination and High-Dose Atypical

    A Systematic Review of Combination and High-Dose Atypical

    APPENDIX 12: STUDY CHARACTERISTICS OF INCLUDED STUDIES Number of Interventions/ Adjunctive Treatment APDs Failed Sample Author, Year Country Sponsor Comparators Medications Duration Prior to Size (Mean Dose) Allowed (Weeks) Study Grant from Stanley Medical research Institute, RIS+CLZ Benzodiazepines Janssen 515.6±138.7 mg/d CLZ for anxiety and/or AKDEDE et al. Pharmaceutica, and 42 Turkey biperiden for 6 weeks ≥3 30 (2005) THE Ritter 5.1±1.3 mg/day RIS EPS allowed if Foundation, the PLC+CLZ necessary William K. 414.3±96.9 mg/d CLZ Warren Medical Research Foundation ANIL YAGCIOGLU et 45 See Akdede 2006 al. (2005) AMI400+CLZ 400mg/d AMI and 300 Occasional mg/d CLZ intake of 49 Sanofi- AMI600+CLZ benzodiazepines, ASSION et al. (2008) Germany 6 weeks ≥1 16 Synthelabo 600 mg/d AMI and sedatives, or 300mg/d CLZ antidepressants PLC+CLZ allowed 300 mg/d CLZ 60 France and Novartis Phama RIS (H): median 9 mg/d AZORIN et al. (2001) Not reported 12 weeks ≥1 273 Canada S.A. CLZ: median: 600 mg/d Lorazepam or Janssen oxazepam for BONDOLFI et al. France and RIS (H): 6.4 mg/d 66 Research sleep induction 8 weeks ≥2 86 (1998) Switzerland CLZ: 291.2 mg/d Foundation or daytime sedation; 156 Systematic Review of Combination and High-Dose AAPs for Schizophrenia Number of Interventions/ Adjunctive Treatment APDs Failed Sample Author, Year Country Sponsor Comparators Medications Duration Prior to Size (Mean Dose) Allowed (Weeks) Study biperiden and procyclidine for EPS Supported by grants from Brain Research center, funded by the ARI+CLZ Antidepressants, Ministry of 15.5±7.1 mg/d ARI and 38 anticholinergics CHANG et al.